Results 51 to 60 of about 21,053 (285)

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response

Physiological Reports, 2022
Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients.
Lixin Fang, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Hiroshi Kawanishi, Tomonobu Takikawa, Yuta Ozaki, Kunihiko Takahara, Minako Tatsumi, Mikito Takefuji, Toyoaki Murohara, Noriyuki Ouchi   +11 more
doaj   +1 more source

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study

Frontiers in Pharmacology, 2023
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management, direct long-term head-to-head comparisons are lacking.
M. Grymonprez, T. D. De Backer, X. Bertels, S. Steurbaut, L. Lahousse   +4 more
semanticscholar   +1 more source

Managing patients taking edoxaban in dentistry [PDF]

, 2017
Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. A new group of oral anticoagulants with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent ...
Curto Aguilera, Adrián, Curto, Daniel, Sanchez, Jorge   +2 more
core   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)

Thrombosis Journal, 2019
Background This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before the study.
Takeshi Yamashita, Joji Hagii, Yoshiyuki Morishima, Takaaki Akasaka, Takuyuki Matsumoto, Tetsuya Kimura   +5 more
doaj   +1 more source

NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]

, 2016
Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne, Hicks, Tim, Stewart, Fiona   +2 more
core   +1 more source

Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach

Cardiovascular Drugs and Therapy, 2023
Purpose We assessed the differential effect of clarithromycin, a strong inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein, on the pharmacokinetics of a regular dose of edoxaban and on a microdose cocktail of factor Xa inhibitors (FXaI ...
Alexander Lenard, S. Hermann, Felicitas Stoll, Juergen Burhenne, K. Foerster, G. Mikus, A. Meid, W. Haefeli, A. Blank   +8 more
semanticscholar   +1 more source

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis and cost-effectiveness analysis [PDF]

, 2017
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH):
Sterne, Jonathan Ac, Bodalia, Pritesh N, Bryden, Peter A, Davies, Philippa A, López-López, Jose A, Okoli, George N, Thom, Howard Hz, Caldwell, Deborah M, Dias, Sofia, Eaton, Diane, Higgins, Julian Pt, Hollingworth, William, Salisbury, Chris, Savović, Jelena, Sofat, Reecha, Stephens-Boal, Annya, Welton, Nicky J, Hingorani, Aroon D   +17 more
core   +3 more sources

The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. [PDF]

, 2017
The ENSURE-AF study (NCT 02072434) of anticoagulation for electrical cardioversion in nonvalvular atrial fibrillation (NVAF) showed comparable low rates of bleeding and thromboembolism between the edoxaban and the enoxaparin-warfarin treatment arms. This
Al-Saady, N, Banach, M, Ezekowitz, MD, Goette, A, Lip, GYH   +4 more
core   +2 more sources

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing

Circulation Reports, 2023
Background Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of rivaroxaban and edoxaban dosing by monitoring plasma concentrations (PCs ...
M. Suwa, Yuki Nohara, I. Morii, M. Kino
semanticscholar   +1 more source